Freeman E, Rickels K, Sondheimer S J, Polansky M
Department of Obstetrics/Gynecology, School of Medicine, University of Pennsylvania, Philadelphia 19104.
JAMA. 1990 Jul 18;264(3):349-53.
Progesterone is the most widely used treatment for premenstrual syndrome. To answer definitely the question of whether progesterone suppositories are effective for the treatment of premenstrual syndrome, a randomized, placebo-controlled, double-blind crossover study of 168 women, receiving progesterone in doses of 400 and 800 mg or placebo, was carried out. Premenstrual symptoms were not significantly improved by progesterone compared with placebo in any measure used in the study, including daily symptom reports maintained throughout treatment, clinician evaluation of improvement, and patient global reports of symptoms severity, relief, and disruption of daily activity. No symptom cluster or individual symptom differed significantly between progesterone and placebo treatment. These treatment results were not significantly affected by fluctuations in response during the placebo washout period, pretreatment levels of depression or anxiety at either postmenstrual or premenstrual times, or any of 19 other background, medical history, or symptom variables examined individually as covariates with treatment.
黄体酮是治疗经前综合征最广泛使用的药物。为了明确回答黄体酮栓剂治疗经前综合征是否有效的问题,对168名女性进行了一项随机、安慰剂对照、双盲交叉研究,这些女性分别接受400毫克和800毫克剂量的黄体酮或安慰剂治疗。在该研究使用的任何衡量标准中,与安慰剂相比,黄体酮均未显著改善经前症状,这些衡量标准包括整个治疗期间的每日症状报告、临床医生对改善情况的评估以及患者对症状严重程度、缓解情况和日常活动干扰的总体报告。在黄体酮和安慰剂治疗之间,没有症状群或个体症状存在显著差异。这些治疗结果在安慰剂洗脱期的反应波动、月经后或经前抑郁或焦虑的预处理水平,或作为治疗协变量单独检查的其他19个背景、病史或症状变量中的任何一个方面,均未受到显著影响。